Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Panobinostat × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 6 Lymphoid 6 Other hematologic neoplasm 2 CNS 1

Conditions

Glioma 3 Diffuse Intrinsic Pontine Glioma 2 Brain Neoplasms 2 Rhabdoid Tumor 1 Recurrence 1 Oligodendroglioma 1 Neoplasms 1 Meningioma 1 Gliosarcoma 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 21 Bevacizumab 18 Cyclophosphamide 7 Lomustine 6 Irinotecan 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 4 Radiosurgery 4 Nivolumab 4 Filgrastim 4 Everolimus 4 Carboplatin 4 fludarabine phosphate 3 Vincristine 3 Sirolimus 3 IL13-PE38 3 Etoposide 3 Drug Therapy 3 Busulfan 3 Antilymphocyte Serum 3 thymoglobulin 2 sonidegib 2 ribociclib 2 pembrolizumab 2 paclitaxel-Angiopep-2 conjugate 2 olaparib 2 fluorodopa F 18 2 fludarabine 2 avapritinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04341311 2024-02-15

DIPG

Dana-Farber Cancer Institute

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡